Evaluation of the effects of curcumin in patients with metabolic syndrome

Saberi‐Karimian, Maryam; Parizadeh, Seyed Mohammad Reza; Ghayour‐Mobarhan, Majid; Salahshooh, Malihe Moammeri; Dizaji, Behdokht Fathi; Safarian, Hamideh; Javandoost, Ali; Ferns, Gordon A.; Sahebkar, Amirhosein; Ahmadinejad, Malihe

doi:10.1007/s00580-017-2624-y

Cited by 36 publications

(47 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Seven studies fulfilled inclusion criteria for quantitative data synthesis. Four studies reported sufficient data on WC (Amin et al, ; Pierro et al, ; Saberi‐Karimian et al, ; Salimi Avansar, ), five reported HDL‐C, TG (Amin et al, ; Panahi et al, ; Saberi‐Karimian et al, ; Salimi Avansar, ; Yang et al, ), and FBS data (Amin et al, ; Panahi et al, ; Saberi‐Karimian et al, ; Salimi Avansar, ; Yang et al, ), and three reported SBP and DBP (Amin et al, ; Y Panahi et al, ; Salimi Avansar, ; Table S2).…”

Section: Resultsmentioning

confidence: 99%

“…The total sample size included 503 MetS participants (224 female/279 male). All studies were parallel RCTs (Amin et al, ; Y Panahi et al, ; Panahi et al, ; Pierro et al, ; Saberi‐Karimian et al, ; Salimi Avansar, ; Yang et al, ). The range of the study's duration was 4 to 12 weeks; four studies lasted 8 weeks (Panahi et al, ; Panahi et al, ; Saberi‐Karimian et al, ) and three studies lasted 4 (Pierro et al, ), 6 (Saberi‐Karimian et al, ), and 12 weeks (Yang et al, ).…”

Section: Resultsmentioning

confidence: 99%

“…Ranges of daily dosages were as follows: 800 mg/day (twice; Pierro et al, ), 1,000 mg/day (twice) (Panahi et al, ; Panahi et al, ; Saberi‐Karimian et al, ), 1,890 mg/day (thrice) (Yang et al, ), 2,400 mg/day (thrice) (Amin et al, ), and one trial based on 20 mg/Kg/day (Salimi Avansar, ).…”

Section: Resultsmentioning

confidence: 99%

“…The disagreement was resolved by the consensus with a third researcher (M. K.). Finally, seven studies met the eligibility criteria (Amin et al, ; Y Panahi et al, ; Panahi et al, ; Pierro et al, ; Saberi‐Karimian et al, ; Salimi Avansar, ; Yang et al, ). The data of these eligible studies were reviewed and abstracted by two researchers independently as follows:…”

Section: Methodsmentioning

confidence: 99%

“…Curcumin can reduce lipid peroxidation (Panahi et al, ) and the risk of cardiovascular factors in patients with type 2 diabetes and dyslipidemia (Panahi et al, ). In another study, curcumin supplementation did not improve anthropometric indices, serum lipid profiles (except TC), systolic blood pressure (SBP), and diastolic blood pressure (DBP) in the patients with MetS (Saberi‐Karimian et al, ).…”

Section: Introductionmentioning

confidence: 96%

See 4 more Smart Citations

Metabolic benefits of curcumin supplementation in patients with metabolic syndrome: A systematic review and meta‐analysis of randomized controlled trials

Azhdari

Karandish

Mansoori

2019

Phytotherapy Research

View full text Add to dashboard Cite

The finding of studies on the effect of curcumin extract on metabolic factor in patients with metabolic syndrome has had arguable results. This systematic review with meta‐analysis of randomized controlled trials (RCT) aimed to analyze the effect of curcumin/turmeric on metabolic factors in patients with metabolic syndrome. The PICO strategy was used to establish the guiding question of this review. Several databases for RCT were searched until September 2018. Of the 144 articles initially identified, seven trials met the eligibility criteria. A random‐effects model with a mean weight difference (WMD) and a 95% confidence interval was performed for quantitative data synthesis. Pooled estimates of WMD were calculated between intervention and control groups using random‐effects model in the presence of high level of heterogeneity between the studies. The results showed significant improvement of fasting blood glucose (p = 0.01), triglycerides (p < 0.001), high‐density lipoprotein cholesterol (p = 0.003), and diastolic blood pressure (p = 0.007) levels. Curcumin was not associated with a significant change in waist circumference measurement (p = 0.6) and systolic blood pressure level (p = 0.269). Curcumin supplementation improves some components of metabolic syndrome.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 96%

See 3 more Smart Citations

Metabolic benefits of curcumin supplementation in patients with metabolic syndrome: A systematic review and meta‐analysis of randomized controlled trials

Azhdari

Karandish

Mansoori

2019

Phytotherapy Research

View full text Add to dashboard Cite

show abstract

Curcumin encapsulation and protection based on lysozyme nanoparticles

Cui

Zhou

Huang

et al. 2019

Food Science & Nutrition

View full text Add to dashboard Cite

Curcumin possesses antioxidant, anti‐inflammatory, and other properties. However, this compound exhibits low bioavailability because of its poor solubility and stability. In this paper, lysozyme nanoparticles were fabricated through solvent evaporation, and then, the solubilization and protection capability of curcumin were investigated. Lysozyme nanoparticles were characterized by dynamic light scattering technique, atomic force microscopy, transmission electron microscopy, and Fourier transform infrared spectroscopy. The load capacity and stability in thermal environment were further explored. Results showed that the lysozyme nanoparticle displayed a spherical structure (127.9 ± 2.12 nm) with favorable distribution. The solubility of curcumin can increase to 22 μg/mL. After encapsulation by lysozyme nanoparticles, the retentive curcumin can reach up to 67.9% and 30.25% at 25°C and 50°C, respectively, significantly higher than that of free curcumin. Meanwhile, experiments on DPPH free radicals indicated the curcumin loaded by lysozyme nanoparticle possessed higher free radical scavenging activity than that of free curcumin with same treatments. The results confirmed that lysozyme nanoparticles exhibit potential applications in solubilizing and protecting the environment‐sensitive hydrophobic functional components.

show abstract

The effects of powdered drinks enriched with curcumin and probiotics on lipid profile and atherogenic indices in patients with metabolic syndrome: A randomized, double‐blinded, placebo‐controlled clinical trial

Mohammadi,

Mohsenpour,

Sohrabi

et al. 2023

Food Science & Nutrition

Self Cite

View full text Add to dashboard Cite

Cardiovascular disease is prevalent globally and is the most common complication of metabolic syndrome (MetS). Previous studies have suggested that curcumin and probiotics may improve the lipid profile, so we aimed to investigate the effects of the edible powder enriched with these substances on lipid profile level and atherogenic indices such as Atherogenic Coefficient (AC), Castelli Risk Index‐I (CRI‐I), Castelli Risk Index‐II (CRI‐II), and Atherogenic Index of Plasma (AIP). In the present parallel randomized double‐blinded placebo‐controlled clinical trial, 124 people with MetS with overweight or obesity were randomly allocated to 4 groups and were followed up for 8 weeks. The participants received a low‐calorie diet and a daily sachet of enriched powder drink. The sachets contained either 109 CFU of probiotics or 1 g of curcumin, or probiotic + curcumin (pro + cur), or placebo, respectively. The fasting lipid profile and atherogenic indices were measured at the beginning and end of the study. One hundred and fourteen participants completed the study. At the end of the study, the within‐ and between‐group comparisons showed no significant differences in lipid profile and atherogenic indices (p > .05). Based on the results of the current study, taking an oral powder containing 1 g curcumin and 109 CFU probiotics for 8 weeks had no effect on the lipid profile level and atherogenic indices; however, more studies are recommended.

show abstract

Evaluation of the effects of curcumin in patients with metabolic syndrome

Cited by 36 publications

References 39 publications

Metabolic benefits of curcumin supplementation in patients with metabolic syndrome: A systematic review and meta‐analysis of randomized controlled trials

Metabolic benefits of curcumin supplementation in patients with metabolic syndrome: A systematic review and meta‐analysis of randomized controlled trials

Curcumin encapsulation and protection based on lysozyme nanoparticles

The effects of powdered drinks enriched with curcumin and probiotics on lipid profile and atherogenic indices in patients with metabolic syndrome: A randomized, double‐blinded, placebo‐controlled clinical trial

Contact Info

Product

Resources

About